Fierce Pharma December 6, 2023
Kevin Dunleavy

Novartis has gained the first of what it hopes are several FDA approvals for its factor B inhibitor iptacopan, dubbed two months ago “a pipeline in pill,” by analysts at ODDO BHF.

The United States regulator has given a thumbs up to iptacopan to treat paroxysmal nocturnal hemoglobinuria (PNH). Known commercially as Fabhalta, it becomes the first oral monotherapy approved by the FDA for the rare blood disorder, which affects 10 to 20 people per one million worldwide.

Novartis has big ambitions for iptacopan and is lining it up to address other complement-mediated renal and hematological diseases, including primary immunoglobulin A nephropathy (IgAN), also known as Berger’s disease. Analysts at Jefferies have pegged iptacopan’s peak sales potential at $3.6 billion.

...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
At Current Prices GLP-1s Aren’t Cost-Effective, Limiting Access To Patients
Latigo raises $150M to get non-opioid pain drugs through key tests
AstraZeneca Aims to Make Cell Therapy More Accessible With $425M EsoBiotec Acquisition
CMS doubles down on Medicare drug price negotiations
Drug shortages could surge 25% as AI reshapes specialty pharmacy: Survey

Share This Article